I Agree

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms of Use.


This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here



It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Fevertree Drinks PLC (FEVR)

Fevertree Drinks PLC

RNS Number : 8775O
Fevertree Drinks PLC
04 June 2020

June 4th, 2020


Fever-Tree Drinks plc



Fever-Tree, the world's leading supplier of premium carbonated mixers, is holding its Annual General Meeting ("AGM") today at 11.30am BST.

At the AGM, Bill Ronald, Chairman of Fever-Tree, will make the following statement:

"As highlighted at the Group's preliminary results in April, although we have been impacted by the COVID-19 crisis, we are well positioned to manage our way through the current situation. We have a fantastic team across the globe who have been working incredibly hard alongside our key customers, suppliers and distribution partners. Our asset light business model continues to support our secure financial position with a FY19 net cash position of £128 million and we benefit from a strong brand portfolio with well-balanced revenue streams across regions, channels and customers.

While the On-Trade remains fully or partially closed across many of our regions, the Group's performance across the Off-Trade continues to be very encouraging. Management remain focused on delivering our long-term strategy and we are confident the Group will be well placed once the current period of uncertainty ends."


COVID-19 Update


On-Trade sales typically represent 50% of UK revenue and continue to be severely impacted by the lockdown. Conversely, our Off-Trade performance has been strong. Sales in the first full month of lockdown were up 24%1 year-on-year and we have seen continued positive momentum since, reflecting increased at home consumption during the period. The core tonic range has performed particularly well, and there has also been notable growth in the convenience channel as consumers increasingly supplement or substitute their trips to large grocery stores.


The US market is naturally weighted to the Off-Trade, which typically contributes 70% to the Group's US revenue. Since the start of lockdown, while On-Trade sales have been severely impacted, Off-Trade sales have grown extremely strongly. Nielsen data, which covers just under half of Fever-Tree's Off-Trade sales in the US, reported 98%2 growth year-on-year for the four weeks to 18th April and 96%2 in the four weeks to the 16th May. Whilst this performance reflects the benefit of incremental distribution that was secured over the course of H2 2019, along with increased at-home consumption during lockdown, it also highlights the growing strength of the Fever-Tree brand, supported by the continued trend towards premium, long drinks. In addition, the Group's US pricing and format optimisation has been very well received by distributors and retailers, with implementation beginning to be seen on-shelf between March and June 2020.


The impacts from COVID-19 have varied across countries within Europe. While Northern Europe is naturally weighted to the Off-Trade and has therefore been more robust, Southern Europe is more reliant on the On-Trade, causing it to be more significantly affected. However, we remain confident in building our momentum in this region over the medium and long-term as premiumisation continues to gain traction. Fever-Tree is the only premium brand with scale across the entire region, with a category leading position in many markets.


While On-Trade challenges have also been evident across the ROW, we are delivering strong Off-Trade sales and continued distribution gains, most notably in Australia and Canada.

Operations and Employees

Our unique asset light, outsourced business model has provided the Group with the flexibility to react to the challenges that COVID-19 presents. We continue to work closely with our suppliers, partners and customers across our supply chain and although there have been some challenges, we continue to maintain continuity of production and supply, as well as the quality of our products.

Fever-Tree continues to support and provide job certainty to all our employees, as well as supporting key workers and the communities in which we operate. We have not furloughed any of our employees regardless of their role and the team remains focused on identifying opportunities that will put us in a strong position as we look to 2021 and beyond. We are also continuing to work closely with our On-Trade partners across our regions, offering support and assistance where relevant as they prepare to re-open.

FY20 outlook

Given the uncertainty and dynamic nature of the situation, it continues to be hard to predict how sales will evolve both during and as we emerge from the lockdown period. The easing of restrictions and the pace at which the On-Trade re-opens will vary between regions, but it is becoming increasingly likely that this process will be gradual and cautious, with social distancing measures remaining in place for some time.

As highlighted at the Group's preliminary results in April, COVID-19 will have a material impact on FY20 trading, with headwinds on gross margin due to changes in channel and territory mix . However, we remain committed to continuing to invest through this period of uncertainty as opportunities arise, particularly in marketing, enabled by the Group's strong balance sheet and conviction in our ability to deliver long-term sustainable growth.

For more information please contact:

Investor queries

Ann Hyams, Director of Investor Relations I ann.hyams@fever-tree.com I +44 (0)7435 828 138

Nominated Advisor and Joint Broker - Numis Securities

Garry Levin I Matt Lewis I Hugo Rubinstein I +44 (0)20 7260 1000

Joint Broker - Investec Bank plc

David Flin I Alex Wright I David Anderson I +44 (0)20 7597 5970


Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024

Brunswick Group I fevertree@brunswickgroup.com I +44 (0) 207 404 5959



1 IRI 4 weeks ending 19 April 2020; 2Nielsen 4 weeks ending 18th April & 16th May

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close